Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) | EXEL Message Board Posts

EXEL   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  22948 of 23103  at  10/20/2019 9:47:38 AM  by

rad.onco


 In response to msg 22947 by  erniewerner
view thread

Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

This ECOG E1512 randomized study was published in Lancet Oncology in 2016 approximately three years ago in previously treated patients with EGFR wild-type NSCLC of adenocarcinoma type prior to all the immunotherapies and routine genetic sequencing searching for various mutations. A four month PFS benefit in such a population at that time in 2016 was significant but unfortunately was not developed further.

https://www.ncbi.nlm.nih.gov/pubmed/27825638


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 253
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
22949 Re: Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) hbomb57108 2 10/20/2019 10:11:52 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...